12:22 PM EST - Medicenna Therapeutics Corp. : Announced virtual presentations of data from its completed Phase 2b trial of MDNA55, an IL4-guided toxin, in patients with recurrent Glioblastoma (rGBM), at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.60 at $7.10.
